Zimmer Biomet Holdings, Inc. reported strong fourth-quarter results with a 10.9% increase in net sales, reaching $2.24 billion, and an adjusted EPS of $2.42, beating analyst expectations by 1.7%. Despite anticipating pricing erosion of up to 100 basis points in 2026, the company is investing in its future with a $1.5 billion share buyback program and plans for significant growth, targeting $9.2 billion in revenue by 2028.
“Zimmer Biomet Holdings, Inc. · posted · fourth-quarter 2025 adjusted earnings per share (EPS) · $2.42”
“Zimmer Biomet Holdings, Inc. · beat · Zacks Consensus Estimate · 1.7%”
“Zimmer Biomet · applies AI in · operating room · integrates machine learning into surgical planning”
“Zimmer Biomet Holdings Inc (NYSE:ZBH) · achieved · sales growth · 5.4%”
“Zimmer Biomet Holdings Inc (NYSE:ZBH) · expects to achieve · full-year organic constant currency revenue growth · 1% to 3%”
“Zimmer Biomet Holdings Inc (NYSE:ZBH) · anticipates · pricing erosion · up to 100 basis points in 2026”
“Zimmer Biomet · gained · +7.27%”
“Zimmer Biomet Holdings, Inc. · reported · fourth-quarter and full-year 2025 results · 2025”
“Zimmer Biomet · completed · a US$1,229.78 million buyback”
“Zimmer Biomet · authorized · a new US$1,500 million repurchase program”
“Zimmer Biomet Holdings · projects · $9.2 billion revenue · by 2028”
“Zimmer Biomet Holdings · projects · $1.3 billion earnings · by 2028”
